The global multiple unit pellet systems (MUPS) market has been valued at USD 3.6 billion in the year 2023, expanding at a CAGR of 3.6% to reach USD 5.2 billion by the end of 2033. According to a recent study, extended-release dosage forms led the market with a share of about 47.1% in 2023.
Granules, pellets, microspheres, microcapsules, and minitablets are examples of MUPS formulations. MUPS formulations are designed to help people swallow capsules more easily and to improve their physicochemical stability in comparison to suspensions. The MUPS formulations have great bioavailability and are very convenient dosage forms. As they are convenient and user-friendly alternatives to regular tablets, MUPS tablets are rapidly gaining traction across the globe.
MUPS tablets and capsules are the most recommended dosage form due to their non-invasiveness, greater patient compliance, and convenience of drug administration. It is used for disease conditions where repeated long-term drug administration is required, such as gastrointestinal and colon drug delivery.
In addition to being convenient and affordable, it is the safest dosage form. This is expected to fuel the growth in the multiple unit pellet systems market over the forecast period. On the back of these aforementioned factors, the sales of multiple unite pellet systems are expected to surge by 1.6x through 2023 & beyond.
| Attributes | Multiple Unit Pellet Systems Market (From 2018 to 2022) |
|---|---|
| CAGR | 2.7% |
| Market Size - 2017 | USD 3.138 billion |
| Market Size - 2022 | USD 3.585 billion |
| Attributes | Multiple Unit Pellet Systems Market (From 2023 to 2033) |
|---|---|
| CAGR | 3.6% |
| Market Size - 2023 | USD 3.6 billion |
| Market Size - 2033 | USD 5.2 billion |
Explore FMI!
Book a free demo
As per Future Market Insights (FMI), the multiple unit pellet systems market accounted for around 20.1% of the overall USD 17.3 billion oral controlled release drug market in 2022. The sales of multiple unit pellet systems expanded at a CAGR of 2.6% from 2018 to 2022, owing to the rise in the use of pellets in drug formulations.
Due to their intrinsic benefits, such as the flexibility they provide when compared with conventional forms, and their ability to provide modified release, immediate release, great therapeutic, and taste-masked formulations, MUPS formulations may continue to gain adoption over traditional drug delivery systems (DDS).
In addition to being manufactured in encapsulated pill, or sachet formats, MUPS assist patients in swallowing drugs more easily, a characteristic that is becoming more crucial in targeted medications for pediatric and geriatric populations.
By incorporating taste and odor masking, numerous dose ranges, and the convenience of administration, MUPS makes complex medications reduces the challenge. Backed by this, the multiple unit pellet systems market is anticipated to record a CAGR of 3.5% during the forecast period.
Increasing the use of pellets in drug formulations is expected to create tremendous opportunities in the MUPS market. Due to the numerous benefits pellets offer to both manufacturers and patients, the use of pellets in drug formulations has gained popularity, boosting the demand for multiple unit pellet system (MUPS) formulations.
Pellets are small, spherical, free-flowing particulates with a variety of skills, one of which is the capacity to create MUPS formulations and multi-drug blends, which is a significant advantage.
Pellets have many benefits for production, from flexibility in combining active compounds into oral dosage forms to the product's overall appearance. Pellets provide a variety of release mechanisms, including sustained, gastro-resistant, and controlled release.
One of the key factors affecting sales negatively is the complex and challenging production process for MUPS tablets. Manufacturing MUPS tablets involves multiple challenges, including particle segregation during compression and compression forces that could harm the functional coating. Understanding the variables influencing coat damage during pellet compression and segregation during tablet manufacturing is essential.
The fragmentation of pellets during compaction into MUPS tablets is another factor limiting the multiple unit pellet systems market growth. The quality of MUPS tablets may be impacted by the excipients used, as well as homogeneous blends of excipients and pellets. Key players are likely to face challenges while developing MUPS formulations due to the factors mentioned above.
| Category | Formulation |
|---|---|
| Leading Segment | Extended Release Dosage Form |
| Market Share | 47.23% |
| Category | Dosage Form |
|---|---|
| Leading Segment | Capsules |
| Market Share | 47.31% |
Capsules to Remain Highly Sought-after Dosage Form in MUPS Market
Regarding formulation, the extended-release dosage form held the leading market share of about 47.23% in the global market in 2023 and is expected to record a CAGR of 3.5% over the forecast period. As extended-release MUPS tablets are largely used in healthcare institutions, growth in the segment is expected to surge.
While based on dosage form, the capsules segment held a revenue share of 41.3% in 2023 and is poised to expand at a CAGR of 3.3% between 2023 and 2033. Capsules are the most preferred dosage form for MUPS due to advantages such as non-invasiveness and patient compliance. Apart from that, the convenience of drug administration is also considered a significant factor pushing the demand for capsules.
Nearly 69% of Multiple Unit Pellet Systems Sales Come from Proton Pump Inhibitors.
Based on the drug class, the proton pump inhibitors segment held a revenue share of 67.9% in 2023, as MUPS of proton pump inhibitors is largely accepted and available across the globe. Based on distribution channels, hospital pharmacies are expected to be the most preferable distribution channel to access the drug class.
As per FMI, the segment held a significant market share value of 32.9% in 2023 and is expected to account for USD 1,595.9 million in revenues in 2033 in the MUPS market due to many patient footfalls in hospitals.
| Countries | Global Market Share - 2033 |
|---|---|
| North America | 29.6% |
| Europe | 25.9% |
Over 9 out of 10 Multiple Unit Pellet Systems Market Sales in North America to be Account by the United States
The United States dominated North American multiple unit pellet systems market with a total demand share of 91.3% in 2023. Growth in the United States market is expected to surge throughout the forecast period owing to the rising prevalence of gastrointestinal disease and growing demand for gastro-resistant drugs.
As per FMI, the United States is expected to spearhead the growth, with sales expected to increase at a steady pace through 2023 & beyond. Demand for MUPS in the United States is expected to rise at 3.2% CAGR, with the country attributing over 91.9% of total sales in the North American market. The United States MUPS market is expected to reach USD 1,325.7 million by the end of 2033.
Increasing Research & Development Activities for Efficient Dosage to Push Sales
FMI estimates India held around 48.5% share in South Asia's multiple unit pellet systems market in 2023 and may display a growth rate of 5.4% between 2023 and 2033. With the need for advanced medicine, India's pharmaceutical manufacturers are increasing research and development spending.
The development of efficient dosage forms of already-approved medications, including MUPS formulations, is facilitated by an increase in the research and development of innovative DDS. By increasing patient compliance, MUPS of PPI, for instance, may enhance the demand for MUPS formulations in India.
On the back of these factors, the demand for multiple unit pellet systems in India is expected to accelerate at 5.4% CAGR during the forecast period. India is expected to spearhead the growth in the South Asia market, contributing over 52% of revenue in 2033.
| Countries | Global Market CAGR (From 2023 to 2033) |
|---|---|
| Australia | 1.8% |
| China | 4.4% |
| India | 5.5% |
| United Kingdom | 3.9% |
Favorable Reimbursement Policies in China to Augment Multiple Unit Pellet Systems Demand
China is set to exhibit a CAGR of nearly 4.3% in the East Asia multiple unit pellet systems market during the forecast period. Due to its efficient drug production, China offers medicines at incredibly affordable costs. The prices of top pharmaceutical brands have decreased by an average of 61% in China due to the updated reimbursement policies.
For instance, it has been claimed that pharmaceutical giants Roche and Novartis have agreed to lower the cost of several of their most recent medications in China. This is expected to aid the growth in China market and improve the sales of novel and potent drug formulations, including MUPS tablets and capsules.
According to the study, Germany held around 20.1% share in the Europe MUPS market in 2023 and is projected to display a growth of 4.1% during the forecast period. Consolidation of the pharmaceutical industry in the European countries, including Germany, combined with expansion in outsourcing for MUPS manufacturing, is boosting the multiple unit pellet systems market.
FMI estimates Germany may account for nearly 22% of the demand share in the Europe market, with sales in the country topping a valuation of USD 279.9 million in 2033. The United Kingdom. It is expected to be the second-leading market in Europe, accounting for around 18.2% of revenue in Europe.
| Countries | Global Market Share (2023) |
|---|---|
| United States | 27.0% |
| Germany | 5.2% |
| Japan | 5.6% |
One of the key factors influencing the rise in the acceptance of multiple unit pellet system (MUPS) formulations is the growth in FDA approvals for pharmaceuticals in the United States. The leading multiple unit pellet system manufacturers are focusing on getting fast-track drug approvals to expand their product portfolio and strengthen their position in the industry.
Recent Developments
The market size of multiple unit pellet systems is to hit USD 5.2 billion by 2033.
The multiple unit pellet system industry is to record a valuation of USD 3.6 billion in 2023.
The multiple unit pellet system industry is likely to secure a CAGR of 3.6% through 2033.
The key players in the global multiple unit pellet systems market are AstraZeneca plc, Merck KGaA, Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Galderma SA, and Novartis AG.
Players opt for mergers and acquisitions.
Generalized Myasthenia Gravis Management Market - Growth & Treatment Advances 2025 to 2035
Hutchinson-Gilford Progeria Syndrome Market Growth – Innovations & Therapies 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Human Combinatorial Antibody Libraries (HuCAL) Market - Trends & Forecast 2025 to 2035
Home Healthcare Market Growth - Trends, Innovations & Forecast 2025 to 2035
Dental 3D Printing Material Market Trends, Growth & Forecast by Material, Product, and Region through 2035
Multiple Unit Pellet Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
